Hyperion DeFi (NASDAQ:HYPD) & Wesana Health (OTCMKTS:WSNAF) Head to Head Comparison

Wesana Health (OTCMKTS:WSNAF) and Hyperion DeFi (NASDAQ:HYPD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Wesana Health and Hyperion DeFi, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Wesana Health	0	0	0	0	0.00
Hyperion DeFi	2	0	2	0	2.00

Hyperion DeFi has a consensus target price of $5.88, suggesting a potential upside of 80.77%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, analysts clearly believe Hyperion DeFi is more favorable than Wesana Health.

Profitability

This table compares Wesana Health and Hyperion DeFi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Wesana Health	N/A	N/A	N/A
Hyperion DeFi	N/A	-138.16%	-94.12%

Earnings and Valuation

This table compares Wesana Health and Hyperion DeFi”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Wesana Health	N/A	N/A	N/A	N/A	N/A
Hyperion DeFi	$810,000.00	45.70	-$45.31 million	($11.80)	-0.28

Wesana Health has higher earnings, but lower revenue than Hyperion DeFi.

Insider and Institutional Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Hyperion DeFi beats Wesana Health on 6 of the 8 factors compared between the two stocks.

About Wesana Health

Wesana Health Holdings Inc. does not have significant operations. Previously, it was developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological, and mental health ailments caused by trauma. The company is headquartered in Chicago, Illinois.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.